Integrated sample preparation and real-time PCR assay for the quantitation of E. coli host cell DNA.
-
Highly sensitive quantitation using proven TaqMan® real-time qPCR technology (Figure 1)
-
Manual and automated sample preparation, optimized for quantitative recovery from complex sample matrices (Table 1)
-
Enables consistent performance across the expected range of DNA fragment sizes (Figure 2)
-
Integrated system from sample to results with sample preparation, master mix, TaqMan® primer/probe mix, and genomic DNA standard
To learn more, click here >>
|
|
|
|
|
|
|
|
|
|
|
|
AstraZeneca and Ardelyx have announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme, including the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodium–hydrogen antiporter 3, a protein essential in the absorption of sodium in the intestines.
Read the full story >>
|
|
 |
|
|
|
|
|
 |
|
New data from ORIGIN
Sanofi announced new results from the landmark ORIGIN (Outcome Reduction with Initial Glargine INtervention) trial showing treatment with Lantus® (insulin glargine) was approximately 3-fold more likely (p<0.001) to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular (CV) risk...
|
|
|
|
|
|
|
|
|
 Date: Thursday 18 October 2012
Time: 3pm BST
Length: 1 hour
A new family or Rapid Micro Method (RMM), real time viable particle detection based on Laser Induced Fluorescence (LIF), has recently been introduced. Sometimes referred to as optical spectroscopy, these instruments provide the ability to continuously measure for the presence of viable particles in real time.
During this webinar an overview of LIF technology will be presented, along with a detailed look at TSI’s implementation in the BioTrak® Real Time Viable Particle Detector highlighting critical instrument performance parameters.
Several application scenarios will be reviewed in the context of current regulatory initiatives such as QbD, ICH Q8, Q9, Q10 and PAT. These applications can form a framework of increased knowledge resulting in a better understanding of the manufacturing process leading to improved product quality in addition to financial benefits.
Register now >>
|
Conferences, events & exhibitions:
2nd Annual Oncology Biomarkers Congress 2012
10 - 11 October 2012 Manchester, UK
Comprehensive Overview of FDA Regulatory Compliance for Drug and Biotech Products
11 - 12 October 2012 Berlin, Germany
Impact of the New European Pharmacovigilance Legislation
15 October 2012 London, UK
Good Manufacturing Practices
15 - 17 October 2012 Dublin, Ireland
Systems Biology Europe
16 - 17 October 2012 Madrid, Spain
Flow Chemistry Asia 2012
25 - 26 October 2012 Singapore
QbD Lifecycle Management for Analytical Methods
25 - 26 October 2012 London, UK
Flow Chemistry India
29 October 2012 Mumbai, India
Indian Lab Automation 2012
30 - 31 October 2012 Mumbai, India
PEGS Europe 2012
6 - 8 November 2012 Vienna, Austria
LAB INNOVATIONS 2012
7 - 8 November 2012 Birmingham NEC, UK
1st International Genomics Research Asia
13 - 14 November 2012 Daejong, South Korea
|
|
Pharmaceuticals: Global Industry Almanac
The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million. In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
OTC Pharmaceuticals: Global Industry Almanac 2011
OTC Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology. Johnson & Johnson reported Remicade sales of $4.6bn in 2010, and the drug is the best-selling “biologic” in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.
|
|
|
